In a prespecified secondary analysis of the AGENT IDE trial, 1-year target lesion failure after paclitaxel-coated balloon for in-stent restenosis was similar in 103 minority vs 303 non-Hispanic White patients (15.0% vs 18.9%; HR 0.79, 95% CI 0.44-1.39; P=0.41).
Secondary analysisn = 406
Jamil et al. Paclitaxel-Coated Balloon for Treating In-Stent Restenosis in Racial and Ethnic Minority Patients: A Subanalysis From the AGENT IDE Trial